Generic Name and Formulations:
Disulfiram 250mg, 500mg; tabs.
Indications for ANTABUSE:
Adjunct in management of chronic alcoholic patients who want to remain sober.
Abstain for at least 12 hrs. Initially 500mg once daily for 1–2 weeks then 250mg once daily; max 500mg daily. Continue until patient develops basis for self-control.
Severe cardiovascular disease. Psychosis. Allergy to thiuram in pesticides and rubber. Concomitant metronidazole, paraldehyde, alcohol-containing products.
Never administer when in a state of alcohol intoxication. Advise family members of alcohol effect. Diabetes. Hypothyroidism. Epilepsy. Cerebral damage. Nephritis. Hepatic cirrhosis or insufficiency. Ethylene dibromide inhalation. Monitor hepatic function, electrolytes, blood, CBCs. Alcohol trial in patients >50yrs: not recommended. Pregnancy. Nursing mothers.
See Contraindications. Alcohol-like reaction to metronidazole, paraldehyde, alcohol-containing drugs and elixirs, some so-called alcohol-free beverages, tonics, foods, aftershave, back rubs. Potentiates phenytoin, oral anticoagulants, isoniazid.
Optic, peripheral and polyneuritis; peripheral neuropathy, drowsiness, rash, psychosis, hepatitis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations